Trials / Completed
CompletedNCT03332186
A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function
A Phase 1, Open-Label, Parallel Group, Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986231 in Subjects With Varying Degrees of Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to investigate experimental medication BMS-986231 in patients with different levels of kidney function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986231 | Intravenous infusion administration |
Timeline
- Start date
- 2018-03-15
- Primary completion
- 2018-10-22
- Completion
- 2018-10-22
- First posted
- 2017-11-06
- Last updated
- 2019-09-11
Locations
3 sites across 2 countries: Czechia, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03332186. Inclusion in this directory is not an endorsement.